Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice

Metabolism: Clinical and Experimental

Volumn 52, Issue 4, 2003, Pages 425-431

  Lukic, Tatjana ^a,b   Wasan, Kishor M ^a,b   Zamfir, Daniela ^a,b   Moghadasian, Mohammed H ^a,b   Pritchard, Haydn ^a,b  

^a Forbes Medi Tech Inc   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ASCORBIC ACID; CARBON DIOXIDE; CHOLESTEROL; DISODIUM ASCORBYLPHYTOSTANYLPHOSPHATE; DRINKING WATER; FAT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; FM VP4 COMPOUND; FM-VP4 COMPOUND; HYPOCHOLESTEROLEMIC AGENT; PHYTOSTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; COMPUTER ANALYSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DOSE RESPONSE; DRUG EFFECT; FOOD INTAKE; GENE DELETION; HEART; HOMOZYGOTE; HYPERLIPOPROTEINEMIA TYPE 3; IMAGE ANALYSIS; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING; STANDARD; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ARTERIOSCLEROSIS; BLOOD; C57BL MOUSE; CYTOCHEMISTRY; DIET; GENETICS; IMAGE PROCESSING; PATHOLOGY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; ASCORBIC ACID; CHOLESTEROL; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTOCYTOCHEMISTRY; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICE; MICE, INBRED C57BL; PHYTOSTEROLS; TRIGLYCERIDES;

EID: 0038413736     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2003.50084     Document Type: Article

References (32)

1. Lacy CR, Suh DC, Barone JA, et al: Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting. Arch Intern Med 62:468-473, 2002
2. Rackley CE: Strategies for the prevention of atherosclerotic progression in women. Cardiol Rev 10:119-125, 2002
3. White CW, Gobel FL, Campeau L, et al: Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation. 2001;104:2660-2665.
4. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440-1445, 1998
5. Wilhelmsen L, Pyorala K, Wedel H, et al: Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J 22:119-127, 2001
6. Sacks FM, Alaupovic P, Moye LA, et al: VLDL, apolipoproteins B, CIII, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102:1886-1892, 2000
7. Gotto AM Jr: Risk factors modification: Rationale for management of dyslipidemia. Am J Med 104:6S-8S, 1998 (suppl)
8. Chitturi S, Farrell GC: Drug-induced cholestasis. Semin Gastrointest Dis 12:113-124, 2001
9. Molden E, Asberg A: Metabolic interactions with statins. Tidsskr Nor Laegeforen. 121:189-193, 2001
10. Penzak SR, Chuck SK, Stajich GV: Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 20:1066-1071, 2000
11. Mussner MJ, Parhofer KG, Von Bergmann K, et al: Effects of phytosterol ester-enriched margarine on plasma lipoprotein in mild to moderate hypercholesterolemia are related to basal cholesterol and fat intake. Metabolism 51:189-194, 2002
12. Nestel P, Cehun M, Pomeroy S, et al: Cholesterol-lowering effects of plant sterol esters and non-esterified stanols in margarine, butter and low-fat foods. Eur J Clin Nutr 55:1084-1090, 2002
13. Plat J, Mensink RP: Effects of plant sterols and stanols on lipid metabolism and cardiovascular risk. Nutr Metab Cardiovasc Dis 11:31-40, 2001
14. Tikkanen MJ, Hogstrom P, Tuomilehto J, et al: Effect of a diet based on low-fat foods enriched with nonesterified plant sterols and mineral nutrients on serum cholesterol. Am J Cardiol 88:1157-1162, 2001
15. Tammi A, Ronnemaa T, Gylling H, et al: Plant stanol ester margarine lowers serum total and low-density lipoprotein cholesterol concentrations of healthy children: The STRIP project. Special Turku Coronary Risk Factors Intervention Project. J Pediatr 136:503-510, 2000
16. Moghadasian MH, McManus BM, Pritchard PH, et al: "Tall oil"-derived phytosterols reduce atherosclerosis in apo E-deficient mice. Arterioscler Thromb Vasc Biol 17:119-126, 1997
17. Moghadasian MH, Frohlich JJ: Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: Clinical and experimental evidence. Am J Med 107:588-594, 1999
18. Moghadasian MH, Godin DV, McManus BM, et al: Lack of regression of atherosclerotic lesions in phytosterol-treated apoE-deficient mice. Life Sci 64:1029-1036, 1999
19. Volger OL, Mensink RP, Plat J, et al: Dietary vegetable oil and wood derived plant stanol esters reduce atherosclerotic lesion size and severity in apoE*3-Leiden transgenic mice. Atherosclerosis 157:375-381, 2001
20. Wasan KM, Peteherych KD, Najafi S, et al: Assessing the plasma pharmacokinetics, tissue distribution, excretion and effects on cholesterol pharmacokinetis of a novel hydrophilic compound, FM-VP4, following administration to rats. J Pharm Pharmaceut Sci 4:207-216, 2001
21. Wasan KM, Holtorf L, Subramanian R, et al: Assessing the plasma pharmacokinetics of cholesterol following oral co-administration with a novel vegetable stanol mixture of fasting rats. J Pharm Sci 90:23-28, 2001
22. Wasan KM, Najafi S, Peteherych KD, et al: Effects of a novel hydrophilic phytostanol analog on plasma lipid concentrations in gerabils. J Pharm Sci 90:1795-1799, 2001
23. Wasan KM, Najafi S, Wong J, et al: Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water soluble phytostanol compound, FM-VP4, to gerbils. J Pharm Pharmaceut Sci 4:228-234, 2001
24. Plump AS, Smith JD, Hayek T, et al: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343-353, 1992
25. Zhang SH, Reddick RL, Piedrahita JA, et al: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468-4671, 1992
26. Palinski W, Ord VA, Plump AS, et al: Apo E-deficient mice are a model of lipoprotein oxidation in atherogenesis; Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 14:605-616, 1994
27. Sehayek E, Shefer S, Nguyen LB, et al: Apo E regulates dietary cholesterol absorption and biliary cholesterol excretion: Studies in C57BL/6 and E-KO mice. Proc Natl Acad Sci USA 97:3433-3437, 2000
28. Moghadasian MH, Nguyen LB, Shefer S, et al: Histologic, hematologic, and biochemical characteristics of apo E-deficient mice: Effects of dietary cholesterol and phytosterols. Lab Invest 79:355-364, 1999
29. Kondo Y, Murakami S, Oda H, et al: Taurine reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Adv Exp Med Biol 483;193-202, 2000
30. Murakami S, Kondo Y, Sakurai T, et al: Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis. 163:79-87, 2002
31. Sumi D, Hayashi T, Thakur NK, et al: A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects-the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 155:347-357, 2001
32. Bracht C, Yan XW, Brunner-LaRocca HP, et al: Isradipine improves endothelium-dependent vasodilation in normotensive coronary artery disease patients with hypercholesterolemia. J Hypertens 19:899-905, 2001